Insulin lispro Sanofi®
ACTIVE PRINCIPLE:
insulin lispro
INDICATION:
Diabetes Mellitus
DATE:
19/07/2017
STATUS:
Authorized
Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE:
insulin lispro
INDICATION:
Diabetes Mellitus
DATE:
19/07/2017
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.